AHA STAT - An American Hospital Association Blog
Facebook Twitter LinkedIn Google+ Pinterest RSS


Reining in drug prices

By AHA STAT Staff
June 13, 2017

A Senate committee today shined the spotlight on the wave of high and unexpected increases in prescription drug costs that puts an incredible financial strain on hospitals and health systems and threaten our ability to provide high quality care each and every day.

In a statement submitted to the committee’s hearing on drug prices, the AHA recommended Congress and the administration move quickly to take a number of steps that would increase competition, transparency, access and... read more

Topic: Advocacy and Public Policy
Tag: drug prices

High Drug Prices Hurt Everyone

By Rick Pollack
October 14, 2016

More evidence this week of how unchecked drug price increases are forcing hospitals to make tough choices and are a serious economic threat to the patients and communities we serve. An AHA/Federation of American Hospitals-commissioned report by the University of Chicago’s NORC showed inpatient hospital drug costs increased more than 38% per admission between 2013 and 2015. An AHA infographic also outlined how rising drug prices are limiting patient access to needed medicines and... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Hospitals, not pharmaceutical manufacturers, are preserving and protecting the safety net

By Tom Nickels
May 17, 2016

A group financed by the pharmaceutical industry is hosting a meeting today on the 340B Drug Pricing Program with the goal of “Preserving the True Safety Net.” But what the meeting really will be about is the pharmaceutical industry – with their skyrocketing prescription drug prices and huge profits – discussing how they can continue to disparage a program with a 25-year history of increasing access to medications and health care services for people in vulnerable communities.

Let’s... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, Community benefit, access, drug prices

Valeant Needs to Keep Its Promises

By Rick Pollack
May 12, 2016

A recent article in the New York Times highlights the yet-to-be-fulfilled promises made by Valeant Pharmaceuticals International to the U.S. Congress. Valeant had said it would give hospitals discounts of as much as 30 percent on two of its expensive heart drugs. But those discounts never materialized and may have been disingenuous. 

New stories illustrating how hospitals and health systems are impacted by rising drug prices and the effect this has on the patients they serve... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Checking Unchecked Rx Prices

By Rick Pollack
April 29, 2016

Unchecked drug price increases hit both patients and hospitals hard. Since 2008, brand name drugs prices have increased 127 percent compared with an 11 percent rise in consumer prices. These increases cut deep into both hospital budgets and services and undermine patient and community health, particularly when patients cannot afford to take their medicines. These increases are simply unsustainable. This week, we joined the Campaign for Sustainable Rx Pricing in support of policy ... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Changing 340B is the wrong prescription for addressing skyrocketing pharmaceutical costs

By Tom Nickels
March 8, 2016

The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.

Many groups, including the AHA, are evaluating options for addressing this important issue. However, one recent proposal, which is seriously misguided, would reduce a program with a 25-year history of increasing access to medications and health care services for people in vulnerable communities in order to add to record profits of drug... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

Stop Unsustainable Drug Prices

By Ashley Thompson
February 4, 2016

Today’s New York Times provides arguments from drug companies justifying the excessive jump in pharmaceutical prices in recent years, saying the higher prices won’t impact patients. 

Hospitals’ top priority is providing patients with safe and effective care, but the skyrocketing costs of pharmaceuticals can make doing so difficult. The high cost of prescription drugs leads to higher out-of-pocket costs for patients, who then may not be able to afford their medications. This may... read more

Topic: Access and Coverage
Tags: access, price, drug prices

Drug Price Hikes Hurt Everyone

By Rick Pollack
December 11, 2015

A Senate committee this week put the spotlight on the wave of increases in the cost of medications. While those truly innovative medicines that save lives and ease suffering are certainly valued by all, the committee’s hearing focused on some of the more troubling of the pharmaceutical industry’s tactics in suddenly jacking up the prices of off-patent drugs. Tactics like Canadian-based Valeant’s purchase earlier this year of the rights to a pair of life-saving heart medications,... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Protect Patients. Preserve 340B.

By AHA STAT Staff
November 19, 2015

More than 20 years ago, Congress created the 340B Drug Pricing Program to allow eligible hospitals and health systems to stretch limited resources and expand access to care for vulnerable patients. But despite a proven track record of increasing patient access to vital medical services and decreasing government spending, some want changes that would weaken the program.   

340B hospitals continue to help care for low-income and uninsured patients. That is why the AHA sponsored... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

340B Proposals Would Jeopardize Hospitals' Ability to Serve Vulnerable Patients

By Tom Nickels
October 27, 2015

The 340B Drug Pricing Program has a strong track record of helping to combat high prescription drug prices and increase access to vital medicines and comprehensive health care services for our nation’s most vulnerable individuals.

However, we are concerned that recent policy changes proposed by the Health Resources and Services Administration (HRSA), the federal agency responsible for administering the 340B program, would jeopardize eligible hospitals’ ability to care for... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, drug prices
 

Search

Twitter

About AHA

Membership

Member Constituency Sections

Key Relationships

News Center

Performance Improvement

Advocacy Issues

Products & Services

Publications

Research & Trends

Locations

155 N. Wacker Dr.
Chicago, Illinois 60606
312.422.3000

800 10th Street, N.W.
Two CityCenter, Suite 400
Washington, DC 20001-4956
202.638.1100

1.800.424-4301